BioFront Therapeutics

BioFront is an incubator discovering and developing FIC/BIC therapeutics targeting unmet medical needs in cardiometabolic and vascular diseases, immuno-oncology and oncology. Company has an innovative DAC platform and more than six early-stage discovery programs, including programs for CKD and obesity. Lead program is a highly selective FPR1 antagonist (BF228) for hemorrhagic stroke